Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and ...

Presented robust CRB-701 clinical data at ESMO 2025 - 3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in ...

Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort versus semaglutide ...

For the second year running, Pfizer has arrived at the European Society for Medical Oncology (ESMO) conference armed with data showing its one-time heart failure hopeful ponsegromab can treat a ...

Battlefield 6 developer Battlefield Studios has addressed XP and progression complaints by outlining plans for a number of key changes to the game. In an update to players, the developer said it was ...

Skye Bioscience’s obesity candidate has failed to reduce weight in a phase 2 study, marking another setback for the CB1 inhibitor class. The biotech had been evaluating a 200-mg weekly subcutaneous ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Skye Bioscience said ...

New data on over 3,000 Google Business Profiles finds proximity drives visibility, but review volume and keyword relevance are most influential near the top. Review count and keywords in reviews are ...

GATESVILLE — Property taxes in Coryell County are increasing by about 8%. The Coryell County Commissioners’ Court unanimously approved a rate of 47.52 cents per $100 valuation. That is about 3.3 cents ...

Semaglutide, a second-generation GLP-1 receptor agonist, was associated with significantly reduced body weight and other metabolic factors in adults with schizophrenia, prediabetes, and ...

Skye shares new preclinical DIO data at virtual KOL event Nimacimab + tirzepatide demonstrates over 40% weight loss in multiple preclinical DIO studies Nimacimab demonstrates durable post-treatment ...